Almirall reports positive trial data for COPD drug

Almirall has published positive data from a new clinical trial of its developmental chronic obstructive pulmonary disease (COPD) drug aclidinium bromide.

The twice-daily drug has been shown to offer benefits in terms of lung function, symptom control and quality of life for moderate to severe COPD sufferers from the first dosage onwards.

Data on the treatment's encouraging performance was collated during a placebo-controlled phase III clinical study called Attain, which evaluated the efficacy of aclidinium bromide for six months among 828 patients.

Additionally, the trial also showed that Almirall's drug offers a favourable safety and tolerability profile, with a minimal risk of anticholinergic adverse events.

Bertil Lindmark, chief scientific officer at Almirall, said: "There is an unmet need for new therapeutic options to improve the health and quality of life of patients living with COPD."

Last week, the company announced a new collaboration with Proteros Biostructures, which will see the firms working together to discover small molecule inhibitors for use in treating inflammatory diseases.